107 results about "Heart Muscle Cell" patented technology

Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix of the invention are provided. Methods of preparing cardiomyocyte culture surfaces and culturing cells with absorbed decellularized cardiac extracellular matrix are provided.

The present disclosure provides induced pluripotent stem (iPS) cells, and induced multipotent stem (iMS) cells, and progeny thereof, which cells include a gene encoding a polypeptide that regulates the QT interval. The present disclosure further provides panels of cardiomyocytes suitable for use in screening compounds for an effect on the QT interval. The cells and panels of cells can be used in a variety of applications, which are also provided.

The invention provides a system and method of analysing the motion of a biological object, particularly the motion of cultured organisms or cell cultures. The system and method of the invention may be used to determine the effect of a physical stimulus or a test agent on the motion of cell cultures. The system and method is of particular use in assessing the effect a chemical may have on the contractile motion of cardiomyocyte cell cultures.

Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media.

The invention provides a method for building a hollow vascularized heart based on the 3D biological printing technology and the hollow vascularized heart and relates to the technical field of tissue engineering and biology. The method includes: performing reverse modeling to build a heart three-dimensional grid model, importing the data of the heart three-dimensional grid model into a double-nozzle biological printing machine, and driving the nozzles of the printing machine to move according to a predesigned CAD digital model and selected forming parameters, wherein the nozzle 1 of the printing machine is loaded with sacrificial materials and used for printing a support framework, the nozzle 2 of the printing machine sprays biological ink to obtain building bodies, and the effective components of the biological ink comprise hydrogel, platelet-rich plasma, third-generation human umbilical vein endothelial cells and SD rat primary cardiomyocytes; crosslinking and cleaning the building bodies, and performing three-dimensional culture to form the hollow vascularized heart. The method has the advantages that the problem that a large-size hollow vascularized heart is hard in integrated printing, and the hollow vascularized heart built by the method is high in cell activity and has certain functions.

Provided are compositions and methods for modulating cardiac cell hypertrophy and hyperplasia using inhibitors of c-Kit activity.

The invention discloses a two-photon fluorescence probe for detecting peroxynitrite as well as a preparation method and application of the two-photon fluorescence probe. The two-photon fluorescence probe has the structural formula as shown in the description. The two-photon fluorescence probe is named as TPNIR-FP. The two-photon fluorescence probe adopts a Nile red derivative as a fluorescent group and an alpha-keto-amide functional group as an ONOO-reaction group, can rapidly respond to ONOO- (within 10 seconds), and in addition is high in sensitivity and good in selectivity. The two-photon fluorescence probe can be applied to imaging research on ONOO- in antharcycline antibiotic induced cardiac muscle cell and cardiac muscle tissue damage.

Methods and compositions are provided for the diagnosis and treatment of heart diseases relating to cardiac hypertrophy, and for the regulation of proliferation and differentiation of cardiomyocyte progenitors in vitro. The detection of expression of components of the BAF complex, including, without limitation, detection of expression of Brg1, provides useful methods for early detection, diagnosis, staging, and monitoring of conditions leading to hypertrophy and enlargement of the heart. Manipulation of Brg1 activity provides for therapeutic intervention in the development of cardiac hypertrophy, where methods of decreasing Brg1 activity, e.g. through inhibition of binding, decreasing expression, and the like, reduces cardiac hypertrophy.

A state space model (SSM), being a computer-calculated model, adapted to represent the pumping and controlling functions of a heart that have been determined by a heart cluster state machine simulating the heart, and optionally the circulatory system, of an individual. The state space model includes two groups of separate interacting state machines, the heart muscle cell state machines and the displacement pump state machines.

The invention relates to compounds of the general formula I, or their isomers, medicinal salts and solvates. The invention also relates to compositions containing the compounds shown of the general formula I, or their isomers, medicinal salts and solvates, and pharmaceutically acceptable carriers, excipients or diluents. The invention further relates to uses of the compounds shown of the general formula I, or their isomers, medicinal salts and solvates in resisting cell apoptosis and preventing or treating of diseases or symptoms related to cell apoptosis, and especially in protecting cardiac muscle cells and preventing or treating diseases or symptoms related to cardiac muscle cell apoptosis.

The invention provides a method for making high-purity camellin A and camellin B. The method is as follows: Adinandra nitida is used as a raw material and is extracted by a hydroalcoholic solvent system; then, the raw material is extracted and degreased by a semipolar organic solvent after depressurized concentration; water-phase continuous concentration of Adinandra nitida total flavone is carried out, and the total flavone is recrystallized to obtain camellin A through a hydroalcoholic system; finally, after the total flavone is turned into camellin B from camellin A by potassium carbonate, camellin B is obtained through ion exchange chromatography or recrystallization directly by the hydroalcoholic system. The invention has reasonable design, simple manufacturing process, low production cost and high yield and purity, and can obtain high-purity camellin A and camellin B through adopting recrystallization method after liquid-liquid extraction; therefore, the invention, omitting the commonly used column chromatography method and reducing the consumption of organic solvent and energy consumption to reduce environmental pollution, is suitable for industrial production. Pharmacological study shows that the method has outstanding protective action on H9C2 cardiac muscle cell line anoxic hypoxia reoxygenation model damage and can be used in curing cardiovascular system disease.

A method for improving embryo dry cell differentiation to heart muscle cell is carried out by placing embryo dry cell culture under low-oxygen environment culturing for some time and oriented inducing. It adopts low-oxygen treatment and has higher acquired rate. It's simple, cheap and controllable.

The invention provides a noni fermented fruit tea and a preparation method thereof. The noni fermented fruit tea is prepared from, by weight, 60-110 parts of noni fruits, 30-46 parts of sweet stevia,25-55 parts of calyx hibisci sabdariffae, 20-60 parts of fructus ligustri lucidi, 3-15 parts of longan flowers, 5-15 parts of semen ziziphi spinosae, 3-12 parts of herba taraxaci, 5-9 parts of fructuslycii, 8-15 parts of fructus jujubae, 5-20 parts of dried dictyophora indusiata, 10-25 parts of bee eggs, 5-10 parts of white sugar and 80-120 parts of coconut water. According to the noni fermentedfruit tea, the noni fruits serve as a main raw material, medical and edible traditional Chinese medical herbs are added, all the raw materials are scientifically proportioned and synergisticallycooperate with one another, and therefore the noni fermented fruit tea has antioxidant activity and a cardiac muscle cell protection effect, can adjust energy metabolism of damaged cardiac muscle cells, andhas the healthcare functions of delaying heart failure, nourishing the liver and the kidney, tonifying qi, invigorating the brain, reducing blood pressure, losing weight and the like; meanwhile, strain fermentation is adopted so that the noni fruits and the traditional Chinese medical herbs can be combined to produce ferment to be made into the fruit tea; a gradient homogenization method is adopted, so that after the raw materials of the noni fermented fruit tea are proportioned, active constituents of all the components are significantly improved.

The present invention provides methods for inducing division of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to repair heart tissue damaged by, for example, myocardial ischemia, hypoxia, stroke, myocardial infarction or chronic ischemic heart disease in vivo. In addition, the methods of the invention can be used to induce heart muscle cells to divide in vitro, in vivo and / or ex vivo, which can then be used in heart tissue repair.

A method for producing autonomously contractile heart muscle cells by cultivating and differentiating stem cells obtained from differentiated exocrine gland tissue of an organism is described. Various uses of the heart muscle cells, in particular in regenerative medicine, are also described.

The present invention provides an immortalized human cardiomyocyte cell line. The present invention further provides a method for preparing a human immortalized cell line derived from a post-mitotic primary cell culture.

The invention provides a method for separate-culturing cardiomyocytes. The method includes the following steps that (1) heart tissue is taken, and PBS liquid is used to wash away residual blood; the heart tissue is cut into tissue blocks of 0.1-1mm<3> with ophthalmic scissors, 0.5-5ml of collagenase I is added, and shaking digesting is carried out at 36-37.5 DEG C for 0.5-3 hours; after digestion,2.5-50mL of PBS is added for dilution and stop, centrifuging is carried out at 1200rpm / min for 5 min, and a supernatant is discarded to obtain a cell pellet; (2) the cell pellet is resuspended with 0.5-5mL pancreatin, an elbow pipette is used for blowing-beating for 10-300 times, after digestion fluid is turbid, a culture medium is added to stop pancreatin digestion, and centrifuging is carried out at 1200rpm / min for 5 min, and a supernatant is discarded to obtain primary cardiomyocytes; and (3) after the primary cardiomyocytes is resuspended in the culture medium, the primary cardiomyocytesare inoculated into the culture medium according to 0.1-10x10<5> cells / cm<2>, and the obtained mixture is placed in a culture incubator of 37 DEG C and 5%CO2 for culturing to obtain the cardiomyocytes.

The invention belongs to the technical field of biomedical engineering, and particularly relates to an artificial cardiac muscle tissue fibrosis model, and a preparation method, a preparation device and an application thereof. The application provides a first artificial cardiac muscle tissue fibrosis model based on human cardiac muscle cells. On one hand, through a tissue engineering technique, humanized artificial cardiac muscle tissue having human body myocardium structure characteristics is constructed, and after uniform and standardized cryodamage treatment, a fibrosis phenotype which is similar to that after miocardial infarction of a human body and is represented by scarring regions produced due to fiber forming cell activation and extracellular matrix deposition can be generated andmake response to medicines; and on the other hand, due to a mature hiPSC-CM disintegration system and a cardiac muscle tissue construction system, the artificial cardiac muscle tissue fibrosis modelcan be constructed at a low cost in batches, test requirements mainly using 96-hole plate for medicine screening are met, the purpose of high-flux medicine test is achieved, and the dilemma that an existing medicine screening system does not have an artificial cardiac muscle fibrosis model for performing related medicine research and development can be avoided.

The invention discloses a novel method for isolating and culturing danio rerio primary cardiomyocytes. The method comprises the following steps: step 1, washing danio rerio by using an A1 solution toremove impurities, and performing washing by using ethanol; step 2, killing the danio rerio, and quickly taking out hearts of the danio rerio; step 3, washing and sterilizing the taken hearts by usingan A2 solution; step 4, finely chopping the hearts by using scissors, and performing blowing by using a cell culture solution A3 to form a single-cell suspension; and step 5, performing centrifugation on the single-cell suspension, removing the cell culture solution A3, adding a cell culture solution A4, and performing culture. According to the method, an average danio rerio heart can obtain about 9.2x10<5> primary cardiomyocytes, and the primary cardiomyocytes can be further used to study the heart development and regeneration function, disease mechanism research, and can also be used to screen small molecule drugs; the method is highly efficient, economical and convenient; the isolated danio rerio primary cells have functionality; and through immunofluorescence identification, the purity reaches 95% or more.

The present invention provides improved systems and methods for the minimally invasive treatment of heart tissue deficiency, damage and / or loss, especially in patients suffering from disorders characterized by insufficient cardiac function, such as congestive heart failure or myocardial infarction. In certain embodiments, a cell composition comprising autologous skeletal myoblasts and, optionally, fibroblasts, cardiomyocytes and / or stem cells, is delivered to a subject's myocardium at or near the site of tissue deficiency, damage or loss, using an intravascular catheter with a deployable needle. Preferably, the cell transplantation is performed after identifying a region of the subject's myocardium in need of treatment. The inventive procedure, which can be repeated several times over time, results in improved structural and / or functional properties of the region treated, as well as in improved overall cardiac function. In particular, the inventive therapeutic methods may be performed on patients that have previously undergone CABG or LVAD implantation.